684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results

BACKGROUND: Preclinical data suggest potential effects of LEF on cardiac interval parameters. We therefore assessed LEF cardiac safety from the LEAP 1/2 trials. METHODS: In LEAP 1, PORT III–V patients received LEF 150mg IV q12h for 5–7 days or MOX 400mg IV q24h for 7 days, with optional IV-to-oral s...

Descripción completa

Detalles Bibliográficos
Autores principales: Darpo, Borje, Das, Anita F, Stein, Daniel, Schranz, Jennifer, Gelone, Steven P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811005/
http://dx.doi.org/10.1093/ofid/ofz360.752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811005/
http://dx.doi.org/10.1093/ofid/ofz360.752

Ejemplares similares